目的:评价BEAM方案预处理条件下的自体造血干细胞移植(ASCT)对复发和难治性非霍奇金淋巴瘤(NHL)的疗效。方法:确诊的侵袭性NHL患者42例,其中难治者23例,复发者19例,经ESHAP化疗方案动员后行BEAM方案预处理ASCT。结果:患者均获得造血功能重建,移植后外周血中性粒细胞计数(ANC)≥0.5×109/L的中位时间为9d(平均7-20d);血小板≥20×109/L中位时间12d(平均6-25d)。随访时间12-78.5个月,中位随访时间35.5个月。中位生存时间32.6个月(2.0-78.5个月),3年总生存率(OS)为55.8%,3年无病生存率(DFS)为44.5%。结论:以BEAM方案化疗进行预处理的ASCT治疗,疗效肯定,患者耐受良好,可以作为复发或难治性侵袭型NHL挽救治疗的理想选择。 OBJECTIVE: To evaluate the efficacy of autologous hematopoietic stem cell transplantation (ASCT) under the BEAM regimen in the treatment of relapsed and refractory non-Hodgkin’s lymphoma (NHL). Methods: Forty-two patients with aggressive NHL were identified, of whom 23 were refractory and 19 were relapsed. BEAM regimen was used to pretreat ASCT after ESHAP chemotherapy. Results: The hematopoietic reconstitution was achieved in all patients. The median time to peripheral blood neutrophil count (ANC) ≥0.5 × 109 / L after transplantation was 9 days (mean, 7-20 days); the median platelet count ≥20 × 109 / L 12d (average 6-25d). Follow-up time was 12-78.5 months, with a median follow-up time of 35.5 months. The median survival time was 32.6 months (2.0-78.5 months). The overall 3-year OS was 55.8% and the 3-year disease-free survival (DFS) was 44.5%. CONCLUSIONS: ASCT with BEAM regimen is a promising treatment for patients with relapsed or refractory invasive NHL.